Skip to main content
NCBI home page
Clinical and Diagnostic Laboratory Immunology logoLink to Clinical and Diagnostic Laboratory Immunology
. 1996 May;3(3):280–286. doi: 10.1128/cdli.3.3.280-286.1996

Neutralizing and enhancing activities of human respiratory syncytial virus-specific antibodies.

H B Gimenez 1, S Chisholm 1, J Dornan 1, P Cash 1
PMCID: PMC170331  PMID: 8705669

Abstract

The neutralizing and enhancing activities of respiratory syncytial virus (RSV)-specific antibodies were examined. These two biological activities were measured for a panel of six monoclonal antibodies (MAbs) specific to the RSV surface F and G glycoproteins. Four MAbs specific for the F protein possessed both neutralizing and enhancing activities. One MAb (11-2-D2), specific to the G protein, enhanced RSV infection of U937 cells, a human macrophage cell line, but did not neutralize virus infectivity. One MAb (11-3-A3), specific to the F protein, efficiently neutralized virus infectivity but did not enhance RSV infection of U937 cells. MAb 11-3-A3 neutralized representative strains of the two antigenic subtypes of RSV. Assays performed with mixtures of MAbs showed that high concentrations of MAb 11-3-A3 masked the enhancing activity of MAb 11-2-D2. The assay of mixtures of two MAbs possessing only enhancing activities demonstrated that this response was synergistic. The role of neutralizing and enhancing antibodies in determining the outcome of RSV infection was examined for infants from whom cord blood serum samples were collected at birth. There was no significant difference in the magnitude of the serum-enhancing activities between infants who were hospitalized with RSV infections and a group of age- and sex-matched control infants with no reported respiratory illness requiring hospitalization. However, the results indicated a possible correlation between RSV infection of the infants and the occurrence of in vitro antibody-dependent enhancement of the cord blood sera at a serum dilution of 10(-2). A significant inverse correlation was found between the plaque-neutralizing and enhancing activities of the cord blood sera from infants, irrespective of subsequent RSV infection. These data are discussed in relation to the possible contribution of antibody-dependent enhancement to the normal course of RSV pathology in vivo.

Full Text

The Full Text of this article is available as a PDF (234.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ananaba G. A., Anderson L. J. Antibody enhancement of respiratory syncytial virus stimulation of leukotriene production by a macrophagelike cell line. J Virol. 1991 Sep;65(9):5052–5060. doi: 10.1128/jvi.65.9.5052-5060.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Anderson L. J., Heilman C. A. Protective and disease-enhancing immune responses to respiratory syncytial virus. J Infect Dis. 1995 Jan;171(1):1–7. doi: 10.1093/infdis/171.1.1. [DOI] [PubMed] [Google Scholar]
  3. Becker S., Soukup J., Yankaskas J. R. Respiratory syncytial virus infection of human primary nasal and bronchial epithelial cell cultures and bronchoalveolar macrophages. Am J Respir Cell Mol Biol. 1992 Apr;6(4):369–374. doi: 10.1165/ajrcmb/6.4.369. [DOI] [PubMed] [Google Scholar]
  4. Cannon M. J., Openshaw P. J., Askonas B. A. Cytotoxic T cells clear virus but augment lung pathology in mice infected with respiratory syncytial virus. J Exp Med. 1988 Sep 1;168(3):1163–1168. doi: 10.1084/jem.168.3.1163. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Chanock R. M., Kapikian A. Z., Mills J., Kim H. W., Parrott R. H. Influence of immunological factors in respiratory syncytial virus disease. Arch Environ Health. 1970 Sep;21(3):347–355. doi: 10.1080/00039896.1970.10667249. [DOI] [PubMed] [Google Scholar]
  6. Chin J., Magoffin R. L., Shearer L. A., Schieble J. H., Lennette E. H. Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. Am J Epidemiol. 1969 Apr;89(4):449–463. doi: 10.1093/oxfordjournals.aje.a120957. [DOI] [PubMed] [Google Scholar]
  7. Cloonan M. J., Hawkes R. A., Stevens L. H. Postnatal decline of maternally acquired rubella antibodies. J Hyg (Lond) 1970 Sep;68(3):461–468. doi: 10.1017/s0022172400042364. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Franke-Ullmann G., Pförtner C., Walter P., Steinmüller C., Lohmann-Matthes M. L., Kobzik L., Freihorst J. Alteration of pulmonary macrophage function by respiratory syncytial virus infection in vitro. J Immunol. 1995 Jan 1;154(1):268–280. [PubMed] [Google Scholar]
  9. Gimenez H. B., Cash P., Melvin W. T. Monoclonal antibodies to human respiratory syncytial virus and their use in comparison of different virus isolates. J Gen Virol. 1984 May;65(Pt 5):963–971. doi: 10.1099/0022-1317-65-5-963. [DOI] [PubMed] [Google Scholar]
  10. Gimenez H. B., Hardman N., Keir H. M., Cash P. Antigenic variation between human respiratory syncytial virus isolates. J Gen Virol. 1986 May;67(Pt 5):863–870. doi: 10.1099/0022-1317-67-5-863. [DOI] [PubMed] [Google Scholar]
  11. Gimenez H. B., Keir H. M., Cash P. In vitro enhancement of respiratory syncytial virus infection of U937 cells by human sera. J Gen Virol. 1989 Jan;70(Pt 1):89–96. doi: 10.1099/0022-1317-70-1-89. [DOI] [PubMed] [Google Scholar]
  12. Glezen W. P., Paredes A., Allison J. E., Taber L. H., Frank A. L. Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level. J Pediatr. 1981 May;98(5):708–715. doi: 10.1016/s0022-3476(81)80829-3. [DOI] [PubMed] [Google Scholar]
  13. Hall C. B., Walsh E. E., Long C. E., Schnabel K. C. Immunity to and frequency of reinfection with respiratory syncytial virus. J Infect Dis. 1991 Apr;163(4):693–698. doi: 10.1093/infdis/163.4.693. [DOI] [PubMed] [Google Scholar]
  14. Halstead S. B. Immune enhancement of viral infection. Prog Allergy. 1982;31:301–364. [PubMed] [Google Scholar]
  15. Hayes P. J., Scott R., Wheeler J. In vivo production of tumour necrosis factor-alpha and interleukin-6 in BALB/c mice inoculated intranasally with a high dose of respiratory syncytial virus. J Med Virol. 1994 Apr;42(4):323–329. doi: 10.1002/jmv.1890420402. [DOI] [PubMed] [Google Scholar]
  16. Homsy J., Meyer M., Levy J. A. Serum enhancement of human immunodeficiency virus (HIV) infection correlates with disease in HIV-infected individuals. J Virol. 1990 Apr;64(4):1437–1440. doi: 10.1128/jvi.64.4.1437-1440.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Kliks S. C., Nimmanitya S., Nisalak A., Burke D. S. Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants. Am J Trop Med Hyg. 1988 Mar;38(2):411–419. doi: 10.4269/ajtmh.1988.38.411. [DOI] [PubMed] [Google Scholar]
  18. Krilov L. R., Anderson L. J., Marcoux L., Bonagura V. R., Wedgwood J. F. Antibody-mediated enhancement of respiratory syncytial virus infection in two monocyte/macrophage cell lines. J Infect Dis. 1989 Nov;160(5):777–782. doi: 10.1093/infdis/160.5.777. [DOI] [PubMed] [Google Scholar]
  19. Leschinskaya N. P., Pokrovskaya E. E., Kantorovitch E. A., Grigorjeva S. K., Shvartsman YaS Ontogenesis of the formation of secretory antibodies to respiratory syncytial (RS) virus. Epidemiol Infect. 1988 Dec;101(3):565–575. doi: 10.1017/s0950268800029435. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Midulla F., Huang Y. T., Gilbert I. A., Cirino N. M., McFadden E. R., Jr, Panuska J. R. Respiratory syncytial virus infection of human cord and adult blood monocytes and alveolar macrophages. Am Rev Respir Dis. 1989 Sep;140(3):771–777. doi: 10.1164/ajrccm/140.3.771. [DOI] [PubMed] [Google Scholar]
  21. Murphy B. R., Graham B. S., Prince G. A., Walsh E. E., Chanock R. M., Karzon D. T., Wright P. F. Serum and nasal-wash immunoglobulin G and A antibody response of infants and children to respiratory syncytial virus F and G glycoproteins following primary infection. J Clin Microbiol. 1986 Jun;23(6):1009–1014. doi: 10.1128/jcm.23.6.1009-1014.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Murphy B. R., Prince G. A., Lawrence L. A., Croen K. D., Collins P. L. Detection of respiratory syncytial virus (RSV) infected cells by in situ hybridization in the lungs of cotton rats immunized with formalin-inactivated virus or purified RSV F and G glycoprotein subunit vaccine and challenged with RSV. Virus Res. 1990 Jun;16(2):153–162. doi: 10.1016/0168-1702(90)90019-8. [DOI] [PubMed] [Google Scholar]
  23. Murphy B. R., Prince G. A., Walsh E. E., Kim H. W., Parrott R. H., Hemming V. G., Rodriguez W. J., Chanock R. M. Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine. J Clin Microbiol. 1986 Aug;24(2):197–202. doi: 10.1128/jcm.24.2.197-202.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Neilson K. A., Yunis E. J. Demonstration of respiratory syncytial virus in an autopsy series. Pediatr Pathol. 1990;10(4):491–502. doi: 10.3109/15513819009067138. [DOI] [PubMed] [Google Scholar]
  25. Ochiai H., Kurokawa M., Kuroki Y., Niwayama S. Infection enhancement of influenza A H1 subtype viruses in macrophage-like P388D1 cells by cross-reactive antibodies. J Med Virol. 1990 Apr;30(4):258–265. doi: 10.1002/jmv.1890300406. [DOI] [PubMed] [Google Scholar]
  26. Osiowy C., Horne D., Anderson R. Antibody-dependent enhancement of respiratory syncytial virus infection by sera from young infants. Clin Diagn Lab Immunol. 1994 Nov;1(6):670–677. doi: 10.1128/cdli.1.6.670-677.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Outlaw M. C., Dimmock N. J. Insights into neutralization of animal viruses gained from study of influenza virus. Epidemiol Infect. 1991 Apr;106(2):205–220. doi: 10.1017/s0950268800048354. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Panuska J. R., Hertz M. I., Taraf H., Villani A., Cirino N. M. Respiratory syncytial virus infection of alveolar macrophages in adult transplant patients. Am Rev Respir Dis. 1992 Apr;145(4 Pt 1):934–939. doi: 10.1164/ajrccm/145.4_Pt_1.934. [DOI] [PubMed] [Google Scholar]
  29. Parrott R. H., Kim H. W., Arrobio J. O., Hodes D. S., Murphy B. R., Brandt C. D., Camargo E., Chanock R. M. Epidemiology of respiratory syncytial virus infection in Washington, D.C. II. Infection and disease with respect to age, immunologic status, race and sex. Am J Epidemiol. 1973 Oct;98(4):289–300. doi: 10.1093/oxfordjournals.aje.a121558. [DOI] [PubMed] [Google Scholar]
  30. Porterfield J. S. Antibody-dependent enhancement of viral infectivity. Adv Virus Res. 1986;31:335–355. doi: 10.1016/s0065-3527(08)60268-7. [DOI] [PubMed] [Google Scholar]
  31. Pringle C. R., Cross A. Neutralisation of respiratory syncytial virus by cat serum. Nature. 1978 Nov 30;276(5687):501–502. doi: 10.1038/276501a0. [DOI] [PubMed] [Google Scholar]
  32. Takala A. K., Meurman O., Kleemola M., Kela E., Rönnberg P. R., Eskola J., Mäkelä P. H. Preceding respiratory infection predisposing for primary and secondary invasive Haemophilus influenzae type b disease. Pediatr Infect Dis J. 1993 Mar;12(3):189–195. doi: 10.1097/00006454-199303000-00003. [DOI] [PubMed] [Google Scholar]
  33. Webster R. G., Askonas B. A. Cross-protection and cross-reactive cytotoxic T cells induced by influenza virus vaccines in mice. Eur J Immunol. 1980 May;10(5):396–401. doi: 10.1002/eji.1830100515. [DOI] [PubMed] [Google Scholar]

Articles from Clinical and Diagnostic Laboratory Immunology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES